Moexipril was given to 35 postmenopausal women with mild and moderate hypertension, menopausal syndrome and decreased bone mineral density. Blood pressure (BP) was measured before and in 1, 3, 6, and 12 months, while ultrasonic bone densitometry was carried out before and in 12 months of moexipril use. Significant lowering of systolic and diastolic BP, reduction of severity of climacteric syndrome occurred after 1, 3 and 6 months of moexipril use, respectively. After 12 months parameters of bone densitometry in moexipril treated women became better than in control group (p<0.01). Treatment was also associated with significant improvement of quality of life, diminished reactive anxiety and depression.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Data on efficacy and safety of angiotensin converting enzyme inhibitor moexipril in the treatment of arterial hypertension are reviewed. Such advantages of this preparation as 24-hour duration of action, lack of loss of hypotensive effect during long term administration, metabolic neutrality, and low rate of side effects are discussed. Antihypertensive action of moexipril is compared with other medicines.
View Article and Find Full Text PDFHypotensive, organoprotective, and metabolic effects of angiotensin converting enzyme inhibitor moexipril (7.5-15 mg/day for 16 weeks) with or without combination with hydrochlorothiazide was studied in 34 women (mean age 59.6+/-1.
View Article and Find Full Text PDFMoexipril (7.4-15 mg/day) was given to 34, spirapril (3-6 mg/day) -- to 18 postmenopausal women with hypertension and metabolic syndrome for 16 weeks. Hydrochlorthiazide was added when therapy was not sufficiently effective.
View Article and Find Full Text PDFAim: To evaluate a hypotensive effect and metabolic neutrality and safety of ACE inhibitor moexipril in postmenopausal women with arterial hypertension (AH), influence on quality of life.
Material And Methods: Thirty two hypertensive postmenopausal women (age 63.1 +/- 0.
Moexipril was given to 35 postmenopausal women with mild and moderate hypertension, menopausal syndrome and decreased bone mineral density. Blood pressure (BP) was measured before and in 1, 3, 6, and 12 months, while ultrasonic bone densitometry was carried out before and in 12 months of moexipril use. Significant lowering of systolic and diastolic BP, reduction of severity of climacteric syndrome occurred after 1, 3 and 6 months of moexipril use, respectively.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!